ClinicalTrials.gg
CompletedNCT00065182Updated Jun 24, 2019Results posted

Comparison of IV Topotecan/Docetaxel to Docetaxel Alone in Second-Line Stage IIIB/IV Non-Small Cell Lung Cancer

A Phase 2 interventional study of Topotecan/Docetaxel combination and Docetaxel in Lung Cancer, Non-Small Cell and Non-Small-Cell Lung Cancer, sponsored by GlaxoSmithKline. Completed at 85 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-06-24.

Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
399
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 198 studies testing docetaxel in Carcinoma, Non-Small-Cell Lung — 13 open to participants now, 20 under way, 3 of them phase 3. Docetaxel · Carcinoma, Non-Small-Cell Lung.

Enrollment
16th of 188
399 · median 50
Started
2003
with 18 others
Phase 2
125 of 198
9 open now
Registered
27th of 198
by date

Among the 198 studies testing docetaxel in Carcinoma, Non-Small-Cell Lung, this one is the 16th largest by enrollment of the 188 interventional ones that give a count, is one of 19 that started in 2003, is one of 125 in phase 2, and was the 27th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

13 of the 198 studies testing docetaxel in Carcinoma, Non-Small-Cell Lung are open now, in 8 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 13 open studies →

About docetaxel

Docetaxel: first FDA approval 1996 (TAXOTERE), first EMA approval 1995. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 198 studies testing docetaxel in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

The purpose of this study is to compare the efficacy and safety of a weekly regimen of two FDA approved drugs in combination versus one FDA approved drug in subjects with advanced non-small cell lung cancer who have received one previous chemotherapy excluding TAXOTERE or HYCAMTIN.

03

Conditions studied

  • Lung Cancer, Non-Small Cell
  • Non-Small-Cell Lung Cancer

Keywords

  • HYCAMTIN
  • TAXOTERE
  • non-small cell lung cancer
  • NSCLC
  • docetaxel
  • topotecan
  • Stage IIIB/IV
  • Advanced
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written
  • At least 18 years old
  • Confirmed advanced non-small cell lung carcinoma (NSCLC)
  • Received one prior chemotherapy for NSCLC excluding TAXOTERE or HYCAMTIN. In addition, subjects are allowed to have previously received a non-cytotoxic therapy, such as an endothelial growth factor receptor (EGFR) or angiogenesis inhibitor.
  • Presence of either measurable or non- by radiologic study or physical examination.
  • Full recovery and at least 21 days from prior treatment for NSCLC; 42 days from treatment with mitomycin or nitrosureas and 30 days from prior non-cytotoxic therapy.
  • At least 3 weeks since last major surgery (a lesser period is acceptable if deemed in the best interest of the patient).
  • At least 7 days since prior radiotherapy.
  • A probable life expectance of at least 3 months.
  • Adequate bone marrow reserve, CBC/, kidney and liver function.

Exclusion criteria

Exclusion criteria:

  • Concomitant or other malignancies within the last five years.
  • Symptoms of requiring treatment with .
  • Active infection.
  • Severe medical problems other than the diagnosis of NSCLC that would limit the ability of the subject to follow study guidelines or expose the subject to extreme risk.
  • Ongoing or planned chemotherapy (other than treatment during this study), immunotherapy, radiotherapy, or therapy for the treatment of NSCLC.
  • Use of investigational drug within 30 days or 5 half-lives prior to the first dose of study medication.
  • Women who are pregnant or lactating.
  • Subjects of refusing to practice adequate .
  • Prior treatment with or history of allergic reaction to either HYCAMTIN or TAXOTERE.
  • Subjects who cannot receive steroid premedication.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
399 participants (actual)

Interventions

06

What researchers measure

Primary outcomes

  1. Median Time of Overall Survival

    Overall survival was defined as the time from randomization to death and it occurs when all randomized participants had at least one year of follow-up past their date of randomization to treatment.

    Time frame: Up to one year from Day -1 (randomization)

Secondary outcomes

  1. Number of Participants With One-year Survival

    Number of participants with one-year survival were planned to be reported.

    Time frame: Up to one year from Day -1 (randomization)

  2. Median Time to Progression

    Time to progression is defined as the time between randomization and the first radiologically or clinically documented evidence of progression.

    Time frame: Up to one year from Day -1 (randomization)

  3. Response Rate

    Response rate is defined as the percentage of participants in the ITT population attaining an overall best response of complete or partial response.

    Time frame: Up to one year from Day -1 (randomization)

  4. Response Duration

    Response duration is defined as the time from initial radiologically documented response to the first radiologically or clinically documented sign of progression.

    Time frame: Up to one year from Day -1 (randomization)

  5. Time to Response-assessed Every 8 Weeks

    Time to response is defined as the time between randomization and the first radiologically documented complete or partial response.

    Time frame: Every 8 Weeks post randomization

  6. Assessment of Quality of Life-assessed Every 4 Weeks

    The effect of treatment regimens on participants-perceived disease status and well-being was assessed using Lung Cancer Symptom Scale (LCSS) that consists of 9 items addressing the time frame of past day: 6 measuring major symptoms for lung malignancies (loss of appetite, fatigue, cough, dyspnea, hemoptysis and pain) and 3 summation items related to total symptomatic distress, activity status and global quality of life. All items are measured by visual analogue scales (VAS) which uses 100 millimeter (mm) lines to determine the intensity of participant responses. The lowest level of symptom intensity or functional disability on the VAS is on left (none) and highest intensity is on right (as much as could be).

    Time frame: Every 4 Weeks post randomization

  7. Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

    AE is defined as any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. SAE is any untoward medical occurrence that, at any dose: results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect or it is considered to be medically significant.

    Time frame: Up to 16 months

  8. Number of Participants With Grade 1, 2, 3 or 4 Hematologic Toxicities

    Hematology parameters included hemoglobin, hematocrit, red blood cell count, white blood cell count with differential leukocyte and platelet count. Differential to include total neutrophils, bands, lymphocytes, monocytes, eosinophil, and basophils. Recording of any hematology toxicity grade was done using National Cancer Institute - Common Toxicity Criteria for Adverse Events (NCI CTCAE) version 2.0. Higher the grade, more is the toxicity. Data for number of participants with grade 1, 2, 3 or 4 hematologic toxicities have been presented.

    Time frame: Up to 16 months

  9. Number of Participants With Grade 3 or 4 Clinical Chemical Toxicities

    Standard chemistry evaluation included sodium, potassium, chloride, bicarbonate, calcium, phosphorous, magnesium, blood urea nitrogen (BUN)/urea, uric acid, creatinine, lactate dehydrogenase (LDH), aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase, total bilirubin, total protein and albumin. Recording of any hematology toxicity grade was done using National Cancer Institute - Common Toxicity Criteria for Adverse Events (NCI CTCAE) version 2.0. Higher the grade, more is the toxicity. Data for number of participants with grade 3 or 4 clinical chemical toxicities have been presented.

    Time frame: Up to 16 months

  10. Number of Participants With Clinically Significant Abnormal Vital Signs Data

    Vital sign parameters included (blood pressure, and pulse rate after five minutes sitting, body temperature). Blood pressure and pulse rate was measured after sitting for 5 minutes. Only participants with clinically significant abnormal Vital sign data was reported.

    Time frame: Up to 16 months

07

Results

Posted Jun 24, 2019
Limitations and caveats
The combination group was terminated as per recommendation of IDMC based on the interim analysis results occurred on 04-November-2005. Therefore all the efficacy parameters were not analyzed.

Participant flow

This was a multicenter study conducted at 62 centers: 11 in Canada, 5 in Poland, and 46 in the United States from 14 August 2003 to 30 August 2007. A total of 399 participants with advanced non-small cell lung cancer (NSCLC) were enrolled in the study and randomized to treatment.

Participant flow — Overall Study
MilestoneIV Topotecan + IV DocetaxelIV Docetaxel
Started202197
Completed154160
Not completed4837
Withdrew: Adverse event2417
Withdrew: Lost to follow-up04
Withdrew: Protocol violation34
Withdrew: Serious adverse events (sae)10
Withdrew: Sponsor decision117
Withdrew: Withdrawal by subject83
Withdrew: No clinical benefit10
Withdrew: Death01
Withdrew: Decline in status01

Outcome measures

PrimaryMedian Time of Overall Survival

Overall survival was defined as the time from randomization to death and it occurs when all randomized participants had at least one year of follow-up past their date of randomization to treatment.

Time frame:
Up to one year from Day -1 (randomization)
Reported as:
Median · Weeks
Median Time of Overall Survival
WeeksIV Topotecan + IV DocetaxelIV Docetaxel
Median Time of Overall Survival30.7 (26.1 to 35.9)28.6 (23.6 to 36.4)
Statistical analysis
  • IV Topotecan + IV Docetaxel vs IV Docetaxel · Log Rank · p = 0.9460 · Hazard ratio (hr): 1.007 · 95% CI 0.813 to 1.248Unadjusted hazard ratio.
  • IV Topotecan + IV Docetaxel vs IV Docetaxel · Hazard ratio (hr): 0.977 · 95% CI 0.788 to 1.210Adjusted hazard ratio.
SecondaryNumber of Participants With One-year Survival

Number of participants with one-year survival were planned to be reported.

Time frame:
Up to one year from Day -1 (randomization)

No measurements were reported for this outcome.

SecondaryMedian Time to Progression

Time to progression is defined as the time between randomization and the first radiologically or clinically documented evidence of progression.

Time frame:
Up to one year from Day -1 (randomization)

No measurements were reported for this outcome.

SecondaryResponse Rate

Response rate is defined as the percentage of participants in the ITT population attaining an overall best response of complete or partial response.

Time frame:
Up to one year from Day -1 (randomization)

No measurements were reported for this outcome.

SecondaryResponse Duration

Response duration is defined as the time from initial radiologically documented response to the first radiologically or clinically documented sign of progression.

Time frame:
Up to one year from Day -1 (randomization)

No measurements were reported for this outcome.

SecondaryTime to Response-assessed Every 8 Weeks

Time to response is defined as the time between randomization and the first radiologically documented complete or partial response.

Time frame:
Every 8 Weeks post randomization

No measurements were reported for this outcome.

SecondaryAssessment of Quality of Life-assessed Every 4 Weeks

The effect of treatment regimens on participants-perceived disease status and well-being was assessed using Lung Cancer Symptom Scale (LCSS) that consists of 9 items addressing the time frame of past day: 6 measuring major symptoms for lung malignancies (loss of appetite, fatigue, cough, dyspnea, hemoptysis and pain) and 3 summation items related to total symptomatic distress, activity status and global quality of life. All items are measured by visual analogue scales (VAS) which uses 100 millimeter (mm) lines to determine the intensity of participant responses. The lowest level of symptom intensity or functional disability on the VAS is on left (none) and highest intensity is on right (as much as could be).

Time frame:
Every 4 Weeks post randomization

No measurements were reported for this outcome.

SecondaryNumber of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

AE is defined as any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. SAE is any untoward medical occurrence that, at any dose: results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect or it is considered to be medically significant.

Time frame:
Up to 16 months
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
ParticipantsIV Topotecan + IV DocetaxelIV Docetaxel
Any AEs186172
Any SAEs5849
SecondaryNumber of Participants With Grade 1, 2, 3 or 4 Hematologic Toxicities

Hematology parameters included hemoglobin, hematocrit, red blood cell count, white blood cell count with differential leukocyte and platelet count. Differential to include total neutrophils, bands, lymphocytes, monocytes, eosinophil, and basophils. Recording of any hematology toxicity grade was done using National Cancer Institute - Common Toxicity Criteria for Adverse Events (NCI CTCAE) version 2.0. Higher the grade, more is the toxicity. Data for number of participants with grade 1, 2, 3 or 4 hematologic toxicities have been presented.

Time frame:
Up to 16 months
Reported as:
Count of participants · Participants
Number of Participants With Grade 1, 2, 3 or 4 Hematologic Toxicities
ParticipantsIV Topotecan + IV DocetaxelIV Docetaxel
Hemoglobin, Grade 176107
Hemoglobin, Grade 29546
Hemoglobin, Grade 31811
Neutrophils, Grade 12714
Neutrophils, Grade 2377
Neutrophils, Grade 3477
Neutrophils, Grade 42011
Platelets, Grade 17510
Platelets, Grade 2203
Platelets, Grade 3180
Platelets, Grade 410
White blood cell, Grade 13828
White blood cell, Grade 25114
White blood cell, Grade 35013
White blood cell, Grade 4152
SecondaryNumber of Participants With Grade 3 or 4 Clinical Chemical Toxicities

Standard chemistry evaluation included sodium, potassium, chloride, bicarbonate, calcium, phosphorous, magnesium, blood urea nitrogen (BUN)/urea, uric acid, creatinine, lactate dehydrogenase (LDH), aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase, total bilirubin, total protein and albumin. Recording of any hematology toxicity grade was done using National Cancer Institute - Common Toxicity Criteria for Adverse Events (NCI CTCAE) version 2.0. Higher the grade, more is the toxicity. Data for number of participants with grade 3 or 4 clinical chemical toxicities have been presented.

Time frame:
Up to 16 months
Reported as:
Count of participants · Participants
Number of Participants With Grade 3 or 4 Clinical Chemical Toxicities
ParticipantsIV Topotecan + IV DocetaxelIV Docetaxel
Albumin, Grade 333
BUN/Urea, Grade 342
Creatinine, Grade 301
Alkaline Phosphatase, Grade 311
AST, Grade 301
AST, Grade 410
ALT, Grade 310
ALT, Grade 410
Bilirubin, Grade 312
Sodium, Grade 3129
Sodium, Grade 401
Calcium, Grade 322
Calcium, Grade 401
Potassium, Grade 373
Potassium, Grade 411
Magnesium, Grade 342
SecondaryNumber of Participants With Clinically Significant Abnormal Vital Signs Data

Vital sign parameters included (blood pressure, and pulse rate after five minutes sitting, body temperature). Blood pressure and pulse rate was measured after sitting for 5 minutes. Only participants with clinically significant abnormal Vital sign data was reported.

Time frame:
Up to 16 months
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Abnormal Vital Signs Data
ParticipantsIV Topotecan + IV DocetaxelIV Docetaxel
Number of Participants With Clinically Significant Abnormal Vital Signs Data00

Adverse events

Collected over Up to 16 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
IV Topotecan + IV Docetaxel170/200 (85%)58/200 (29%)181/200 (90.5%)
IV Docetaxel165/195 (84.6%)49/195 (25.1%)166/195 (85.1%)
Most frequent serious events
Showing 10 of 73
Most frequent serious events
EventIV Topotecan + IV DocetaxelIV Docetaxel
Febrile neutropeniaBlood and lymphatic system disorders6/2007/195
PneumoniaInfections and infestations7/2004/195
AnaemiaBlood and lymphatic system disorders6/2000/195
DehydrationMetabolism and nutrition disorders6/2002/195
DyspnoeaRespiratory, thoracic and mediastinal disorders5/2001/195
Pulmonary embolismRespiratory, thoracic and mediastinal disorders0/2004/195
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders3/2001/195
DiarrhoeaGastrointestinal disorders3/2002/195
ThrombocytopeniaBlood and lymphatic system disorders3/2000/195
NauseaGastrointestinal disorders1/2002/195
Most frequent other events
Showing 10 of 43
Most frequent other events
EventIV Topotecan + IV DocetaxelIV Docetaxel
FatigueGeneral disorders90/20074/195
NauseaGastrointestinal disorders57/20043/195
DiarrhoeaGastrointestinal disorders51/20040/195
DyspnoeaRespiratory, thoracic and mediastinal disorders46/20036/195
AnaemiaBlood and lymphatic system disorders44/20021/195
ConstipationGastrointestinal disorders39/20038/195
AnorexiaMetabolism and nutrition disorders33/20037/195
AlopeciaSkin and subcutaneous tissue disorders36/20035/195
NeutropeniaBlood and lymphatic system disorders34/2009/195
Oedema peripheralGeneral disorders28/20031/195

Baseline characteristics

Age, Customized
Age, Customized(Participants)IV Topotecan + IV DocetaxelIV DocetaxelTotal
18-40415
41-64129116245
>=656980149
Sex: Female, Male
Sex: Female, Male(Participants)IV Topotecan + IV DocetaxelIV DocetaxelTotal
Female6378141
Male139119258
Race (NIH/OMB)
Race (NIH/OMB)(Participants)IV Topotecan + IV DocetaxelIV DocetaxelTotal
American Indian or Alaska Native000
Asian516
Native Hawaiian or Other Pacific Islander000
Black or African American101323
White184183367
More than one race000
Unknown or Not Reported303
08

Study locations

85 sites
  • GSK Investigational Site
    Huntsville, Alabama 35801, United States
  • GSK Investigational Site
    Mobile, Alabama 36608, United States
  • GSK Investigational Site
    Tucson, Arizona 85712, United States
  • GSK Investigational Site
    Little Rock, Arkansas 72205, United States
  • GSK Investigational Site
    Fresno, California 93720, United States
  • GSK Investigational Site
    Los Angeles, California 90067, United States
  • GSK Investigational Site
    Poway, California 92064, United States
  • GSK Investigational Site
    Denver, Colorado 80210, United States
  • GSK Investigational Site
    Washington, District of Columbia 20307-5001, United States
  • GSK Investigational Site
    Washington, District of Columbia 20422, United States
  • GSK Investigational Site
    Boca Raton, Florida 33428, United States
  • GSK Investigational Site
    Boca Raton, Florida 33486, United States
  • GSK Investigational Site
    Lakeland, Florida 33805, United States
  • GSK Investigational Site
    Miami Shores, Florida 33138, United States
  • GSK Investigational Site
    Orange Park, Florida 32073, United States
  • GSK Investigational Site
    Orlando, Florida 32804, United States
  • GSK Investigational Site
    Stuart, Florida 34994, United States
  • GSK Investigational Site
    Columbus, Georgia 31902, United States
  • GSK Investigational Site
    Decatur, Illinois 62526, United States
  • GSK Investigational Site
    Elk Grove Village, Illinois 60007, United States
  • GSK Investigational Site
    Skokie, Illinois 60077, United States
  • GSK Investigational Site
    Urbana, Illinois 61801, United States
  • GSK Investigational Site
    Indianapolis, Indiana 46202, United States
  • GSK Investigational Site
    Bowling Green, Kentucky 42101, United States
  • GSK Investigational Site
    Louisville, Kentucky 40207, United States
  • GSK Investigational Site
    Louisville, Kentucky 40215, United States
  • GSK Investigational Site
    Baton Rouge, Louisiana 70808, United States
  • GSK Investigational Site
    Lafayette, Louisiana 70506, United States
  • GSK Investigational Site
    Lake Charles, Louisiana 70601, United States
  • GSK Investigational Site
    Frederick, Maryland 21701, United States
  • GSK Investigational Site
    Boston, Massachusetts 02118, United States
  • GSK Investigational Site
    Grosse Pointe Woods, Michigan 48236, United States
  • GSK Investigational Site
    Minneapolis, Minnesota 55407-3799, United States
  • GSK Investigational Site
    Minneapolis, Minnesota 55417, United States
  • GSK Investigational Site
    Robbinsdale, Minnesota 55422, United States
  • GSK Investigational Site
    Saint Louis, Missouri 63141, United States
  • GSK Investigational Site
    Springfield, Missouri 65807, United States
  • GSK Investigational Site
    Las Vegas, Nevada 89106, United States
  • GSK Investigational Site
    Reno, Nevada 89502, United States
  • GSK Investigational Site
    Hackensack, New Jersey 07601, United States
  • GSK Investigational Site
    Bronx, New York 10467, United States
  • GSK Investigational Site
    Buffalo, New York 14215-1199, United States
  • GSK Investigational Site
    East Syracuse, New York 13057, United States
  • GSK Investigational Site
    Manhasset, New York 11030, United States
  • GSK Investigational Site
    New Hyde Park, New York 11040, United States
  • GSK Investigational Site
    Nyack, New York 10960, United States
  • GSK Investigational Site
    Rochester, New York 14623, United States
  • GSK Investigational Site
    Fayetteville, North Carolina 28302-2000, United States
  • GSK Investigational Site
    Winston-Salem, North Carolina 27103, United States
  • GSK Investigational Site
    Canton, Ohio 44718, United States
  • GSK Investigational Site
    Dunmore, Pennsylvania 18512, United States
  • GSK Investigational Site
    Philadelphia, Pennsylvania 19114, United States
  • GSK Investigational Site
    Columbia, South Carolina 29203, United States
  • GSK Investigational Site
    Hilton Head Island, South Carolina 29926, United States
  • GSK Investigational Site
    Spartanburg, South Carolina 29303, United States
  • GSK Investigational Site
    Knoxville, Tennessee 37916, United States
  • GSK Investigational Site
    Nashville, Tennessee 37203, United States
  • GSK Investigational Site
    Irving, Texas 75038, United States
  • GSK Investigational Site
    Tyler, Texas 75701, United States
  • GSK Investigational Site
    Abingdon, Virginia 24211, United States
  • GSK Investigational Site
    Norfolk, Virginia 23502, United States
  • GSK Investigational Site
    Norfolk, Virginia 23507, United States
  • GSK Investigational Site
    Spokane, Washington 99204, United States
  • GSK Investigational Site
    Tacoma, Washington 98405, United States
  • GSK Investigational Site
    Milwaukee, Wisconsin 53295, United States
  • GSK Investigational Site
    Sheboygan, Wisconsin 53081, United States
  • GSK Investigational Site
    Casper, Wyoming 85601, United States
  • GSK Investigational Site
    Calgary, Alberta T2N 4N2, Canada
  • GSK Investigational Site
    Moncton, New Brunswick E1C 8X3, Canada
  • GSK Investigational Site
    Kingston, Ontario K7L 5P9, Canada
  • GSK Investigational Site
    Kitchener, Ontario N2G 1G3, Canada
  • GSK Investigational Site
    London, Ontario N6A 4L6, Canada
  • GSK Investigational Site
    Ottawa, Ontario K1H 1C4, Canada
  • GSK Investigational Site
    St. Catharines, Ontario L2R 5K3, Canada
  • GSK Investigational Site
    Toronto, Ontario M5G 1X5, Canada
  • GSK Investigational Site
    Toronto, Ontario M5G 2M9, Canada
  • GSK Investigational Site
    Weston, Ontario M9N 1N8, Canada
  • GSK Investigational Site
    Greenfield Park, Quebec J4V 2H1, Canada
  • GSK Investigational Site
    Levis, Quebec G6V 3Z1, Canada
  • GSK Investigational Site
    Sainte-Foy, Quebec G1V 4G5, Canada
  • GSK Investigational Site
    Kielce, 25-640, Poland
  • GSK Investigational Site
    Krakow, 31-115, Poland
  • GSK Investigational Site
    Olsztyn, 10-228, Poland
  • GSK Investigational Site
    Poznan, 60-569, Poland
  • GSK Investigational Site
    Szczecin Zdunowo 20, 70-891, Poland
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2003 to primary completion in Aug 2007, 48 months.

Results were first posted in Jun 2019, 11 years 9 months after primary completion.

Of 317 industry-sponsored phase 2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 59. This study's 48 months is above that.

Counting every sponsor, half of 1,047 studies reached it within 48 months; a quarter within 30 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 17, 2003
First posted
Jul 18, 2003
StartActual
Aug 14, 2003
Primary completionActual
Aug 30, 2007
CompletionActual
Aug 30, 2007
Results first posted
Jun 24, 2019
Last update
Jun 24, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 24, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00065182
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Jul 18, 2003
Start date
Aug 14, 2003
Primary completion
Aug 30, 2007
Completion
Aug 30, 2007
Results posted
Jun 24, 2019
Last update
Jun 24, 2019

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Topotecan · Docetaxel

Start the discussion